Opioids affect inflammation and the immune system

Pain Reviews

Volumn 5, Issue 3, 1998, Pages 147-154

  Krajnik, Malgorzata ^a   Finlay, Ilora G ^b   Zylicz, Zbigniew ^b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Holme Tower Marie Curie Centre ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BETA ENDORPHIN; CALCITONIN GENE RELATED PEPTIDE; CATECHOLAMINE; CORTICOTROPIN RELEASING FACTOR; DIAMORPHINE; ENDOTHELIN; GALANIN; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALTREXONE; NEUROKININ A; NEUROPEPTIDE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE PEPTIDE; OPIATE RECEPTOR; PREPROENKEPHALIN; PROSTAGLANDIN; SOMATOSTATIN; SUBSTANCE P; TACHYKININ RECEPTOR; THROMBOXANE B2; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTHRITIS; ASTHMA; CONSTIPATION; HUMAN; HYPERALGESIA; IMMUNE SYSTEM; INFLAMMATION; MIGRAINE; NATURAL KILLER CELL; NONHUMAN; PAIN; PRURITUS; REVIEW; T LYMPHOCYTE;

EID: 0031763289     PISSN: 09681302     EISSN: None     Source Type: Journal    
DOI: 10.1191/096813098673417837     Document Type: Review

References (74)

1. Krajnik M, Zylicz Z. Topical opioids - fact or fiction. Prog Palliat Care 1997; 5: 101-106.
2. Lotz M, Carson D, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1988; 235: 893-95.
3. Koch TR, Carney JA, Go VL, Szurszewski JH. Spontaneous contractions and some electrophysiologic properties of circular muscle from normal sigmoid colon and ulcerative colitis. Gastroenterology 1988; 95: 77-84.
4. Lundberg JM, Saria A. Capsaicin-induced desensitisation of airway mucosa to cigarette smoke, mechanical and chemical irritants. Nature 1983; 302: 251-53.
5. Barnes PJ. Neurogenic inflammation in asthma. J Asthma 1992; 29: 165-80.
6. Saria A. Substance P in sensory nerve fibers contributes to the development of oedema in the rat hindpaw after thermal injury. Br J Pharmacol 1984; 323: 341-42.
7. Green PG, Basbaum AI, Helms C, Levine JD. Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat. Proc Natl Acad Sci USA 1991; 88: 4162-65.
8. Coderre TJ, Basbaum AI, Levine JD. Neural control of vascular permeability: interactions between primary afferents, as cells, and sympathetic efferents. J Neurophysiol 1989; 62: 48-58.
9. Levine JD, Fields HL, Basbaum AI. Peptides and the primary afferent nociceptor. J Neurosci 1993; 13: 2273-86.
10. Dray A. Tasting the inflammatory soup: the role of peripheral neurones. Pain Reviews 1994; 1: 153-71.
11. Wiertelak EP, Smith KP, Furness L et al. Acute and conditioned hyperalgesic responses to illness. Pain 1994; 56: 227-34.
12. Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991; 44: 293-99.
13. Yaksh TL. Substance P release from knee joint afferent terminals: modulation by opioids. Brain Res 1988; 458: 319-24.
14. Brodin E, Gazelius B, Panopoulos P, Olgart L. Morphine inhibits substance P release from peripheral sensory nerve endings. Acta Physiol Scand 1983; 117: 567-70.
15. White DM, Helme RD. Release of SP from peripheral nerve terminals following electrical stimulation of the sciatic nerve. Brain Res 1985; 336: 27-31.
16. Appelboom T, DeMaertelaer V, DePrez E, Hauzer JP and Deschodt-Lancman M. Enkephalinase: a physiologic neuroimmunomodulator detected in the synovial fluid. Arthritis Rheum 1991; 34: 1048-51.
17. Sakurada T, Katsumata K, Yogo H et al. The neurokinin-1 receptor antagonist, sendide, exhibits antinociceptive activity in the formalin test. Pain 1995; 60: 175-80.
18. Dmitrieva N, McMahon SB. Sensitization of visceral afferents by nerve growth factor in the adult rat. Pain 1996; 66: 87-97.
19. Rueff A, Dawson AJLR, Mendell LM. Characteristics of nerve growth factor induced hyperalgesia in adult rats: dependence on enhanced bradykinin-1 receptor activity but not neurokinin-1 receptor activity. Pain 1996; 66: 359-72.
20. Apfel SC, Newel M, Dormia C, Kessler JA. Kappa opioid receptors participate in nerve growth factor-induced hyperalgesia. Neuroscience 1995; 68: 1199-206.
21. Donnerer J, Schuligoi R, Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience 1992; 49: 693-98.
22. Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci 1993; 16: 353-59.
23. Shen KF, Grain SM. NGF rapidly prolongs the action potential of mature sensory ganglion neurons in culture, and this effect requires activation of Gs-coupled excitatory k-opioid receptors on these cells. J Neurosci 1994; 14: 5570-79.
24. Otten U, Ehrhard P, Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA 1989; 86: 10059-63.
25. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophine to neurokine. Trends Neurosci 1996; 19: 514-20.
26. Lundberg JM, Saria A. Bronchial smooth muscle contraction induced by stimulation of capsaicin-sensitive sensory neurons. Acta Physiol Scand 1982; 116: 473-76.
27. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of proinflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995; 63: 289-302.
28. Bjurholm A, Kreiebergs A, Ahmed M, Schultzberg M. Noradrenergic and peptidergic nerves in the synovial membrane of the Sprague-Dawley rat. Arthritis Rheum 1990; 33: 859-65.
29. Brandli P, Loffler BM, Breu V, Osterwalder R, Maire JP, Clozel M. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 1995; 64: 315-22.
30. Glinski W, Brodecka H, Glinska-Ferenz M, Kowalski D. Neuropeptides in psoriasis: possible role of B-endorphin in the pathomechanism of the disease. Int J Dermatol 1994; 33: 356-60.
31. Green PG, Levine JD. Delta- and kappa-opioid agonists inhibit plasma extravasation induced by bradykinin in the knee joint of the rat. Neuroscience 1992; 49: 129-33.
32. Gyires K, Budavari I, Furst S, Molnar I. Morphine inhibits the carageenan-induced oedema and the chemoluminescence of leukocytes stimulated by zymosan. J Pharm Pharmacol 1985; 37: 100-104.
33. Lei YH, Barnes PJ, Rogers DF. Mechanisms and modulation of airway plasma exudation after direct inhalation of cigarette smoke. Am J Respir Crit Care Med 1995; 151: 1752-62.
34. Barber A, Gottschlich R. Opioid agonists and antagonists: an evaluation of their peripheral actions in inflammation. Med Res Rev 1992; 12: 525-62.
35. Russel NJW, Schaible HG, Schmidt RF. Opiates inhibit the discharges of fine afferent units from inflamed knee joint of the cat. Neurosci Lett 1987; 76: 107-12.
36. Stein C, Millan MJ, Schippenberg TS, Peter K, Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 1989; 248: 1269-75.
37. Watkins LR, Wiertelak EP, Goehler LE et al. Neurocircuitry of illness-induced hyperalgesia. Brain Res 1994; 639: 283-99.
38. Watkins LR, Maier SF, Goehler LE. Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Life Sci 1995; 57: 1011-26.
39. Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of cytokine-induced hyperalgesia. Brain Res 1994; 654: 15-26.
40. Czlonkowski A, Stein C, Herz A. Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. Eur J Pharmacol 1993; 242: 229-35.
41. Schafer M, Carter L, Stein C. Interleukin 1 B and corticotropin-releasing factor inhibits pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci USA 1994; 91: 4219-23.
42. Cabot PJ, Carter L, Gaiddon C et al. Immune cell-derived beta-endorphin - production release and control of inflammatory pain in rats. J Clin Invest 1997; 100: 142-48.
43. Schafer M, Mousa SA, Zhang Q, Carter L, Stein C. Expression of corticotropin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. Proc Natl Acad Sci USA 1996; 93: 6096-100.
44. Stein C, Hassan AHS, Lehrberger K, Giefing J, Yassouridis A. Local analgesic effect of endogenous opioid peptides. Lancet 1993; 342: 321-24.
45. Stein C, Schafer M, Carter L et al. Cytokine-induced antinociception mediated by opioids released from immune cells. Regul Pept 1994; 50: S191-92.
46. Stanfa L, Dickenson A, Xu XJ, Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol Sci 1994; 15: 65-66.
47. Stanfa LC, Sullivan AF, Dickenson AH. Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan induced inflammation. Pain 1992; 50: 345-54.
48. Stanfa LC, Dickenson AH. Enhanced alpha-2 adrenergic controls and spinal morphine potency in inflammation. NeuroReport 1994; 5: 469-72.
49. Carr DJJ. The role of endogenous opioids and their receptors in the immune system. Proc Soc Exp Biol Med 1991; 198: 710-20.
50. Smith EM, Blalock JE. Human lymphocyte production of corticotropin and endorphin-Iike substances: association with leukocyte interferon. Proc Natl Acad Sci USA 1981; 78: 7530-34.
51. Zurawski G, Benedik M, Kamb BJ et al. Activation of mouse T-helper cells induces abundant preproenkephalin mRNA synthesis. Science 1986; 232: 772-75.
52. Bostwick DG, Null WE, Holmes D, Weber E, Barchas JD, Bensch KG. Expression of opioid peptides in tumors. N Engl J Med 1987; 317: 1439-43.
53. Johnson HM, Smith EM, Torres BA, Blalock JE. Regulation of the in vitro antibody response by neuroendocrine hormones. Proc Natl Acad Sci USA 1982; 79: 4171-74.
54. Lolait SJ, Clements JA, Markwick AJ et al. Pro-opiomelanocortin messenger ribonucleic acid and posttranslational processing of beta endorphin in spleen macrophages. J Clin Invest 1986; 77: 1776-79.
55. Oison GA, Olson RD, Kastin AJ. Endogenous opiates: 1995. Peptides 1996; 17: 1421-66.
56. Carr DJJ, Radulescu RT, DeCosta BR, Rice KC, Blalock JE. Opioid modulation of immunoglobulin production by lymphocytes isolated from Peyer's patches and spleen. Ann N Y Acad Sci 1992; 650: 125-27.
57. Chang KJ. Opioid peptides have actions on the immune system.Trends Neurosci 1984; 7: 234-35.
58. Stefano GB, Digenis A, Spector S et al. Opiate-like substances in an invertebrate, an opiate receptor on invertebrate and human immunocytes, and a role in immunosuppression. Proc Natl Acad Sci USA 1993; 90: 11099-103.
59. Wybran J. Enkephalins and endorphins as modifiers of the immune system: present and future. Fed Proc 1985; 44: 92-94.
60. Lysle DT, Hoffman KE, Dykstra LA. Evidence for the involvement of the caudal region of the periaqueductal gray in a subset of morphine-induced alterations of immune status. J Pharmacol Exp Ther 1996; 277: 1533-40.
61. Hamra JG, Yaksh TL. Equianalgesic doses of subcutaneous but not intrathecal morphine alter phenotypic expression of cell surface markers and mitogen-induced proliferation in rat lymphocytes. Anesthesiology 1996; 85: 355-65.
62. Buzzetti R, McLoughlin L, Lavender PM, Clark AJL, Rees LH. Expression of pro-opioimelanocortin gene and quantification of adrenocorticotropic hormone-like immunoreactivity in human normal peripheral mononuclear cells and lymphoid and myeloid malignancies. J Clin Invest 1989; 83: 733-37.
63. Fiorica E, Spestor S. Opioid binding site in EL-4 thymoma cell line. Life Sci 1987; 42: 199-206.
64. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science 1983; 221: 671-73.
65. Bryant HU, Roudebush RE. Suppressive effects of morphine pellet implants on in vivo parameters of immune function. J Pharmacol Exp Ther 1990; 255: 410-14.
66. Taub DD, Eisenstein TK, Geller EB, Adler MW, Rogers TJ. Immunomodulatory activity of u- and k-selective opioid agonists. Proc Natl Acad Sci USA 1991; 88: 360-64.
67. Breitbart W, Rosenfeld BD, Passik SD, McDonald MV, Thaler H, Portenoy RK. The undertreatment of pain in ambulatory AIDS patients. Pain 1996; 65: 243-49.
68. Singer EJ, Zorilla C, Fahy-Chandon B, Chi S, Syndulko K, Tourtellotte WW. Painful symptoms repeated by ambulatory HIV-infected men in a longitudinal study. Pain 1993; 54: 15-19.
69. O'Neill WM, Sherrard JS. Pain in human immunodeficiency virus disease: a review. Pain 1993; 54: 3-14.
70. Breitbart W, Passik SD, Lefkowitz M, Patt RB, Reddy KS. Pain in AIDS: a call for action. Pain Clin Updates 1996; 4: 1-4.
71. Breitbart W, McDonald MV, Rosenfeld B et al. Pain in ambulatory AIDS patients. I: Pain characteristics and medical correlates. Pain 1996; 68: 315-21
72. Hosokawa T, Fujiwara A, Nakagawa H, Omori M, Tanaka Y. Immunological changes in chronic pain patients [Abstracts]. 7th World Congress on Pain; 1993 Aug 22-27; Paris, 45.
73. Chalmers DT, Lovenberg TW, Gridoriadis DE, Behan DP, DeSouza EB. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci 1996; 17: 166-72.
74. Oluyomi AO, Poole S, Smith TW, Hart SL. Antinociceptive activity of peptides related to interleukin-1B-(193-195), Lys-Pro-Thr. Eur J Pharmacol 1994; 258: 131-38.